Michael Estepan News Today

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month […]

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its target price hoisted by Mizuho from $145.00 to $179.00 in a report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Mizuho’s target price would suggest a potential upside of 36.25% from the stock’s previous close. A number […]

Cantor Fitzgerald reiterated their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research report report published on Thursday morning, Benzinga reports. They currently have a $128.00 target price on the biotechnology company’s stock. Other equities analysts also recently issued research reports about the company. Wedbush reissued an outperform rating and […]

Sapient Capital LLC purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,146 shares of the biotechnology company’s stock, valued at approximately $978,000. Several other institutional investors also recently bought […]

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a research report issued on Thursday, Benzinga reports. They presently have a $166.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price objective would suggest a potential upside of 26.81% […]

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) – Zacks Research lowered their Q2 2024 EPS estimates for shares of Sarepta Therapeutics in a research note issued on Monday, April 29th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn ($0.06) per share for the quarter, down from their prior estimate of […]

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) – Stock analysts at William Blair reduced their FY2024 EPS estimates for Sarepta Therapeutics in a research report issued on Wednesday, April 17th. William Blair analyst T. Lugo now forecasts that the biotechnology company will post earnings per share of $6.66 for the year, down from their previous […]

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has earned an average rating of “Moderate Buy” from the fifteen analysts that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month target price […]